← All categories

US Stocks — 28 / 41

US Stocks, page 28 of 41 — 24 articles published 2026-07-14 ~ 2026-07-16.

SMMT Summit Therapeutics Stock Outlook 2026: The Drug That Beat Keytruda, and Whether the Data Holds

SMMT Summit Therapeutics Stock Outlook 2026: The Drug That Beat Keytruda, and Whether the Data Holds

Summit Therapeutics (SMMT) stock analysis for 2026: ivonescimab's PD-1/VEGF bispecific mechanism, the head-to-head win over Keytruda in lung cancer, the Akeso license structure, single-asset concentration risk, the China-to-global data translatability question, and Robert Duggan's outsized role — a qualitative framework for a clinical-stage biotech.

SMMT Summit Therapeutics Ivonescimab